Transarterial chemoembolization in patients with hepatocellular carcinoma

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)

Abstract

Curative therapies for hepatocellular carcinoma, such as liver transplantation, liver resection and percutaneous ablation can be applied to in a small number of patients (30-40%) with hepatocellular carcinoma. In patients with advanced stages different palliative therapies had been tested. Arterial embolization with or without chemotherapy had been one of the most used therapies. The ideal candidates for this option are patients with well-preserved liver function with multinodular asymptomatic tumours without vascular invasion. In these cases, objective response rates of 30-50% can be achieved, with an increase in patient's survival. The procedure is quite sure and the treatment-related mortality is less than 4%, and the most frequent complication is the so-called postembolization syndrome. With the intention to reduce tumoral progression during the stay in the waiting list for liver transplantation, most centres uses chemoembolization as a bridge to liver transplantation. However, there is insufficient evidence that chemoembolization offers any benefit when used prior to liver transplant, neither for early nor for advanced HCC. Copyright © 2008 Aran Ediciones, s. l.
Original languageEnglish
Pages (from-to)59-66
JournalRevisiones en Cancer
Volume22
Issue number2
Publication statusPublished - 1 Jan 2008

Keywords

  • Arterial chemoembolization
  • Arterial embolization
  • Hepatocellular carcinoma

Fingerprint Dive into the research topics of 'Transarterial chemoembolization in patients with hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this